SCHEMBL9926301

SCHEMBL9926301

C[C@H]1CCCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL254704 1.00
SCHEMBL31121560 1.00
SCHEMBL37613 1.00
SCHEMBL28458927 0.97
SCHEMBL8223766 0.97
SCHEMBL23648162 0.97
SCHEMBL28199160 0.97
SCHEMBL250240 0.97
SCHEMBL3346847 0.97
Ammonia Solution, Strong SCHEMBL4765003 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398136-B2 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors VENTUS THERAPEUTICS U.S., INC. (US) 2025-08-26 US disclosed
US-12331048-B2 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors VENTUS THERAPEUTICS U.S., INC. (US) 2025-06-17 US disclosed
US-20240409540-A1 PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U S INC (US) 2024-12-12 US disclosed
US-20240383896-A1 PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U.S., INC. 2024-11-21 US disclosed
US-20240360130-A1 PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U.S., INC. 2024-10-31 US disclosed
WO-2024218296-A1 COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS H. LUNDBECK A/S (DK) 2024-10-24 WO disclosed
WO-2024148091-A1 CDK2 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2024-07-11 WO disclosed
US-20240209132-A1 COUPLING OF 2,3,5-TRIMETHYLHYDROQUINONE AND UNSATURATED ALCOHOLS DSM IP ASSETS B.V. (NL) 2024-06-27 US disclosed
US-20240209132-A1 COUPLING OF 2,3,5-TRIMETHYLHYDROQUINONE AND UNSATURATED ALCOHOLS DSM IP ASSETS B.V. (NL) 2024-06-27 US disclosed
WO-2024129881-A1 COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING WAVEBREAK THERAPEUTICS LIMITED (US) 2024-06-20 WO disclosed
US-20090312288-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-17 US disclosed
US-20090246686-A1 POLYMER, POLYMER PREPARATION METHOD, RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-10-01 US disclosed
EP-2096117-A1 Process for producing erythromycin derivative Chugai Seiyaku Kabushiki Kaisha (JP) 2009-09-02 EP disclosed
US-20090192214-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG (CH) 2009-07-30 US disclosed
US-20090192214-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG (CH) 2009-07-30 US disclosed
US-20090111801-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US disclosed
US-20090111801-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US disclosed
WO-2007122173-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
WO-2007025089-A2 TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICAL, INC. (US) 2007-03-01 WO disclosed
EP-0385662-A2 Heterocycles with inhibitory activity of 5-lipoxygenase ZENECA LIMITED (GB) 1990-09-05 EP disclosed